iCo-007: Final Phase I data

Final data from an open-label, dose-escalation, U.S. Phase I trial in 15 patients showed that single intravitreal injections of iCo-007 reduced excess retinal thickness by 40%. Additionally, iCo-007 led to stable or improved vision in 9 of 13 patients who completed 24 weeks of follow up. ...